Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimodSUCHIN, Karen Rebecca; JUNKINS-HOPKINS, Jacqueline M; ROOK, Alain H et al.Archives of dermatology (1960). 2002, Vol 138, Num 9, pp 1137-1139, issn 0003-987X, 3 p.Article

Successful reversal of severe refractory cardiac allograft rejection by photopheresisLEHRER, Michael S; ROOK, Alain H; TOMASZEWSKI, John E et al.The Journal of heart and lung transplantation. 2001, Vol 20, Num 11, pp 1233-1236, issn 1053-2498Article

Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoidesLEE, Jin; RICHARDSON, Stephen K; MELHEM, Elias R et al.Journal of the American Academy of Dermatology. 2007, Vol 57, Num 5, pp 893-895, issn 0190-9622, 3 p.Article

Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activityYOO, Elisa K; CASSIN, Maureen; LESSIN, Stuart R et al.Journal of the American Academy of Dermatology. 2001, Vol 45, Num 2, pp 208-216, issn 0190-9622Article

T_H2 Cytokines from Malignant Cells Suppress T_H1 Responses and Enforce a Global T_H2 Bias in Leukemic Cutaneous T-cell LymphomaGUENOVA, Emmanuella; WATANABE, Rei; FISHER, David C et al.Clinical cancer research (Print). 2013, Vol 19, Num 14, pp 3755-3763, issn 1078-0432, 9 p.Article

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patientsKELLY-SELL, Michael J; KIM, Youn H; ROOK, Alain H et al.American journal of hematology. 2012, Vol 87, Num 4, pp 354-360, issn 0361-8609, 7 p.Article

High Clinical Response Rate of Sezary Syndrome to Immunomodulatory Therapies: Prognostic Markers of ResponseRAPHAEL, Brian A; SHIN, Daniel B; ROOK, Alain H et al.Archives of dermatology (1960). 2011, Vol 147, Num 12, pp 1410-1415, issn 0003-987X, 6 p.Article

Increased Programmed Death-1 Expression on CD4⁺ T Cells in Cutaneous T-Cell Lymphoma: Implications for Immune SuppressionSAMIMI, Sara; BENOIT, Bernice; EVANS, Katherine et al.Archives of dermatology (1960). 2010, Vol 146, Num 12, pp 1382-1388, issn 0003-987X, 7 p.Article

Clinical and in vitro resistance to bexarotene in adult T-cell leukemia : loss of RXR-a receptorLIN, Julie H; KIM, Ellen J; ROOK, Alain H et al.Blood. 2008, Vol 112, Num 6, pp 2484-2488, issn 0006-4971, 5 p.Article

A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesDUVIC, Madeleine; SHERMAN, Matthew L; WOOD, Gary S et al.Journal of the American Academy of Dermatology. 2006, Vol 55, Num 5, pp 807-813, issn 0190-9622, 7 p.Article

Progressive Multifocal Leukoencephalopathy Associated With Brentuximab Vedotin Therapy: A Report of 5 Cases from the Southern Network on Adverse Reactions (SONAR) ProjectCARSON, Kenneth R; NEWSOME, Scott D; LANDSBURG, Daniel et al.Cancer. 2014, Vol 120, Num 16, pp 2464-2471, issn 0008-543X, 8 p.Article

Extracorporeal photopheresis: Past, present, and futureKNOBLER, Robert; BARR, Mark L; COURIEL, Daniel R et al.Journal of the American Academy of Dermatology. 2009, Vol 61, Num 4, pp 652-665, issn 0190-9622, 14 p.Article

Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell LymphomaGARDNER, Jennifer M; EVANS, Katherine G; GOLDSTEIN, Steven et al.Archives of dermatology (1960). 2009, Vol 145, Num 9, pp 985-988, issn 0003-987X, 4 p.Article

Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosisAVARBOCK, Andrew B; LOREN, Alison W; PARK, Jason Y et al.American journal of hematology. 2008, Vol 83, Num 7, pp 593-595, issn 0361-8609, 3 p.Article

Biological effects of bexarotene in cutaneous T-cell lymphomaBUDGIN, Jeanne B; RICHARDSON, Stephen K; NEWTON, Sarah B et al.Archives of dermatology (1960). 2005, Vol 141, Num 3, pp 315-321, issn 0003-987X, 7 p.Article

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15WYSOCKA, Maria; BENOIT, Bernice M; NEWTON, Sarah et al.Blood. 2004, Vol 104, Num 13, pp 4142-4149, issn 0006-4971, 8 p.Article

Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet a for a patient with refractory stage IVa cutaneous T-cell lymphomaSHAPIRO, Michael; ROOK, Alain H; LEHRER, Michael S et al.Journal of the American Academy of Dermatology. 2002, Vol 47, Num 6, pp 956-961, issn 0190-9622, 6 p.Article

Primary cutaneous aggressive epidermotropic CD8⁺ T-cell lymphomaGORMLEY, Rachel H; HESS, Stephen D; ANAND, Dipti et al.Journal of the American Academy of Dermatology. 2010, Vol 62, Num 2, pp 300-307, issn 0190-9622, 8 p.Article

A novel regimen of vorinostat with interferon gamma for refractory Sézary syndromeGARDNER, Jennifer M; INTROCASO, Camille E; NASTA, Sunita D et al.Journal of the American Academy of Dermatology. 2009, Vol 61, Num 1, pp 112-116, issn 0190-9622, 5 p.Article

Differential Effects of Interleukin-2 and Interleukin-15 versus Interleukin-21 on CD4+ Cutaneous T-Cell Lymphoma CellsMARZEC, Michal; HALASA, Krzysztof; WASIK, Mariusz A et al.Cancer research (Baltimore). 2008, Vol 68, Num 4, pp 1083-1091, issn 0008-5472, 9 p.Article

Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expressionCONTASSOT, Emmanuel; KERL, Katrin; ROQUES, Stéphanie et al.Blood. 2008, Vol 111, Num 9, pp 4780-4787, issn 0006-4971, 8 p.Article

Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimenSHAPIRO, Michael; WASIK, Mariusz A; JUNKINS-HOPKINS, Jacqueline M et al.American journal of hematology. 2003, Vol 74, Num 1, pp 46-51, issn 0361-8609, 6 p.Article

Denileukin diftitox for the treatment of panniculitic lymphomaMCGINNIS, Karen S; SHAPIRO, Michael; JUNKINS-HOPKINS, Jacqueline M et al.Archives of dermatology (1960). 2002, Vol 138, Num 6, pp 740-742, issn 0003-987XArticle

Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: A 14-year experience at a single institutionSUCHIN, Karen Rebecca; CUCCHIARA, Andrew J; GOTTLEIB, Scott L et al.Archives of dermatology (1960). 2002, Vol 138, Num 8, pp 1054-1060, issn 0003-987XArticle

Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomasSHAPIRO, Michael; YUN, Mijin; JUNKINS-HOPKINS, Jacqueline M et al.Journal of the American Academy of Dermatology. 2002, Vol 47, Num 4, pp 623-628, issn 0190-9622, 6 p.Article